Natixis Athersys, Inc Transaction History

Natixis

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.6 - $1.06 $21,000 - $37,100	-35,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.41 - $1.94 $49,350 - $67,900	35,000 New	35,000 $53,000
Q1 2021 May 14, 2021	SELL	$1.61 - $2.77 $56,350 - $96,950	-35,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.24 $54,250 - $78,400	35,000 New	35,000 $63,000
Q1 2020 May 14, 2020	SELL	$1.17 - $3.0 $46,800 - $120,000	-40,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$1.21 - $1.65 $48,400 - $66,000	40,000 New	40,000 $53,000
Q1 2019 May 15, 2019	SELL	$1.39 - $1.71 $55,599 - $68,400	-40,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.41 - $2.16 $56,400 - $86,400	40,000 New	40,000 $58,000
Q3 2018 Nov 14, 2018	SELL	$1.86 - $2.18 $74,400 - $87,200	-40,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$1.76 - $2.79 $3,974 - $6,299	-2,258 Reduced 5.34%	40,000 $79,000
Q1 2018 May 15, 2018	SELL	$1.34 - $2.03 $151 - $229	-113 Reduced 0.27%	42,258 $77,000
Q4 2017 Feb 14, 2018	SELL	$1.65 - $2.45 $17,049 - $25,315	-10,333 Reduced 19.61%	42,371 $80,000
Q3 2017 Nov 14, 2017	BUY	$1.5 - $2.55 $79,056 - $134,395	52,704	52,704 $108,000

Ticker ATHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 305,110,016
Market Cap $3.05M
Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.